Mabwell(SH:688062) Xin Lang Cai Jing·2025-10-16 02:41Core Viewpoint - Maiwei Biotech's stock has shown significant volatility and growth, with a notable increase in share price and trading activity, indicating investor interest and market dynamics [1][2]. Group 1: Stock Performance - As of October 16, Maiwei Biotech's stock price increased by 2.18%, reaching 48.25 CNY per share, with a trading volume of 226 million CNY and a turnover rate of 2.34%, resulting in a total market capitalization of 19.281 billion CNY [1]. - Year-to-date, the stock price has risen by 138.86%, with a 1.84% increase over the last five trading days, a 2.92% decrease over the last 20 days, and a 55.09% increase over the last 60 days [1]. - The company has appeared on the "龙虎榜" (a list of stocks with significant trading activity) five times this year, with the most recent appearance on September 2 [1]. Group 2: Financial Performance - For the first half of 2025, Maiwei Biotech reported a revenue of 101 million CNY, a year-on-year decrease of 12.43%, and a net profit attributable to shareholders of -551 million CNY, reflecting a year-on-year decrease of 23.90% [2]. - As of June 30, 2025, the number of shareholders increased to 17,900, up by 11.66%, while the average number of circulating shares per person decreased by 10.44% to 11,379 shares [2]. Group 3: Shareholder Composition - As of June 30, 2025, Hong Kong Central Clearing Limited became the third-largest circulating shareholder with 4.7426 million shares, marking its entry as a new shareholder [2]. - Xingquan Helun Mixed A and Penghua Medical Technology Stock A are among the top ten circulating shareholders, with the former holding 3.39 million shares and the latter holding 3.1056 million shares, the latter having decreased its holdings by 1.173 million shares compared to the previous period [2].